Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Disparities in RCC Trial Access Illuminate the Need for Global Scientific Collaboration

March 3rd 2025

Regina Barragan-Carrillo, MD, discusses a study of RCC clinical trial availability and barriers to opening RCC clinical trials in lower-income countries.

Addition of CBM588 to Cabozantinib/Nivolumab Shows Potential in Metastatic RCC

March 3rd 2025

Hedyeh Ebrahimi, MD, MPH, highlights the early activity of CBM588 plus cabozantinib/nivolumab for the treatment of patients with metastatic RCC.

CHMP Recommends Perioperative Durvalumab Regimen in Resectable NSCLC

March 3rd 2025

The CHMP has recommended the approval of perioperative durvalumab plus neoadjuvant chemotherapy for patients with resectable NSCLC.

Rusfertide Meets Response End Point in Phlebotomy-Dependent Polycythemia Vera

March 3rd 2025

Rusfertide improved responses vs placebo in phlebotomy-dependent polycythemia vera.

T-DXd Improves OS in Unresectable/Metastatic HER2+ Gastric/GEJ Adenocarcinoma

March 3rd 2025

T-DXd improved overall survival in unresectable/metastatic HER2-positive gastric/GEJ adenocarcinoma after a trastuzumab-containing regimen.

TNBC Awareness Day Emphasizes Progress in Treatment Strategies

March 3rd 2025

Angela Jain, MD, discussed the current treatment paradigm in triple-negative breast cancer (TNBC), including currently investigated therapies, during TNBC Awareness Day.

Clinical Trials, Randomized Data Are Key to Further Refine Treatment Selection in Advanced Non–Clear Cell RCC

February 27th 2025

Charles B. Nguyen, MD, provides insight into current challenges faced in the non–clear cell RCC landscape beyond the NCCN’s recent guideline updates.

First-Line Camizestrant Plus CDK4/6 Inhibition Boosts PFS in ESR1+, HR+/HER2-Negative Advanced Breast Cancer

February 26th 2025

Camizestrant plus a CDK4/6 inhibitor was safe and effective in frontline ESR1-mutated HR-positive/HER2-negative advanced breast cancer.

FDA Accepts Resubmission of BLA for Odronextamab in R/R Follicular Lymphoma

February 26th 2025

The resubmission of a BLA for odronextamab was accepted by the FDA for the treatment of patients with relapsed/refractory follicular lymphoma.

Ibrutinib/Venetoclax/Obinutuzumab Controls Disease at 5 Years in Newly Diagnosed MCL

February 25th 2025

At 5 years of follow-up, sustained disease control was demonstrated with ibrutinib plus venetoclax and obinutuzumab in patients with newly diagnosed MCL.

Time-Limited Zanubrutinib/Rituximab Yields Durable Remissions in Treatment-Naive CLL

February 24th 2025

Time-limited zanubrutinib/rituximab was well tolerated and continued to elicit remissions 13 months after treatment discontinuation in treatment-naive CLL.

AUTX-703 Receives FDA Fast Track Designation in Relapsed/Refractory AML

February 24th 2025

The FDA has granted the novel, oral KAT2A/B degrader AUTX-703 fast track designation for the treatment of patients with relapsed/refractory AML.

FDA Accepts sBLA for Nivolumab/Ipilimumab in Unresectable/Metastatic MSI-H/dMMR CRC

February 24th 2025

The combination of nivolumab and ipilimumab is under priority review for the frontline treatment of patients with unresectable/metastatic MSI-H/dMMR CRC.

Key HCC Trial Data Establish the Role of Later-Line Cabozantinib and Raise Further Frontline Questions

February 20th 2025

Gentry King, MD, discusses positive and negative outcomes following the phase 3 CELESTIAL and COSMIC-312 trials in patients with hepatocellular carcinoma.

Epcoritamab Elicits Durable CR Rates, Increases MRD Negativity in Relapsed/Refractory DLBCL

February 20th 2025

Julie M. Vose, MD, MBA, discusses the 3-year follow-up data with epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Immune Checkpoint Inhibitors Retain Their Role in the HCC Treatment Paradigm

February 19th 2025

Gentry King, MD, highlights the evolution of treatments in the hepatocellular carcinoma landscape and the impact of the phase 3 HIMALAYA trial.

Global Survey Outlines Optimal Population for Surgical Treatment of Proximal Femur Metastases

February 19th 2025

R. Lor Randall, MD, FACS, discusses the enrollment criteria for a trial investigating surgical outcomes in patients with proximal femur metastases.

Biomarker-Driven Research Accelerates Drug Discovery and Precision Medicine Approaches in Sarcoma

February 18th 2025

Neeta Somaiah, MD, highlights the evolving sarcoma treatment paradigm within the past 5 years, including the FDA approval of afamitresgene autoleucel.

FDA Grants Priority Review to Dordaviprone in Recurrent H3K27M+ Diffuse Glioma

February 18th 2025

The FDA has accepted and granted priority review to an NDA for dordaviprone in recurrent H3K28M-mutant diffuse glioma.

Tivozanib Elicits Similar PROs With or Without Nivolumab in Advanced Clear Cell RCC

February 15th 2025

No significant differences in PROs were shown between the tivozanib/nivolumab and tivozanib monotherapy arms in patients with advanced clear cell RCC.